FDA approval puts Loxo Bayers Vitrakvi on the rails to valuebased care

FDA approval puts Loxo, Bayer’s Vitrakvi on the rails to value-based care

That the drug will only be given to patients shown through testing to harbor a genetic anomaly that increases the odds of a response makes its approval an important milestone in the evolution of value-based care.

More From BioPortfolio on "FDA approval puts Loxo, Bayer’s Vitrakvi on the rails to value-based care"